Kellogg Company Sets Date for 2017 4th Quarter Results Business Call / Webcast

Fight CREEK, Mi., 12 ,. 7, 2017 /PRNewswire/ — Kellogg Company (New york stock exchange: K) intends to issue its 2017 4th quarter financial results at roughly 8:00 am EST on Thursday, Feb 8, 2018. 

The next documents is going to be available online, http://investor.kelloggs.com, at 8:00 am EST: Pr release, financial tables, GAAP reconciliations, and presentation slides. 

The organization may also host an open business call / webcast where Kellogg executive management will review and discuss these results. Speaking with respect to Kellogg Company is going to be Steve Cahillane, Ceo and Fareed Khan, Chief Financial Officer. An issue and answer session with analysts and investors follows.  A transcript from the business call is going to be published on the organization website within 24 hrs from the event.

Live Business Call

Date:                       

Thursday, Feb 8, 2018

Time:                    

9:30 am – 10:30 am EST

Teleconference Number:   

(855) 209-8258 within the U.S. 

(412) 542-4104 outdoors the U.S.

Dial-in available beginning at 9:15 am EST, no access code needed.

Presentation Slides:    

Printable slides offered at roughly 8:00 am EST on Thursday, Feb 8 at http://investor.kelloggs.com. 

Webcast:                

Live audio webcast without or with slides can be obtained at http://investor.kelloggs.com. 

Participation through the press within the live Q&A session is within a listen-only mode.

Rebroadcast                      

Webcast:             

Available beginning at 1:00 pm EST Thursday, Feb 8, and not less than 3 months after that at http://investor.kelloggs.com. 

Podcast:             

MP3 audio file (podcast) readily available for download beginning at approximately 1:00 pm EST on Thursday, Feb 8, at http://investor.kelloggs.com.

Telephonic:            

Available beginning at 1:30 pm EST Thursday, Feb 8,
until Thursday, Feb 15, 2018.

(877) 344-7529 within the U.S., access code # 10114272

(412) 317-0088 outdoors the U.S., access code # 10114272

About Kellogg Company

At Kellogg Company (New york stock exchange: K), we’re driven to enhance and delight the planet through foods and types that matter. With 2016 sales in excess of $13 billion, Kellogg may be the world’s leading cereal company second largest producer of cookies and crackers a number one producer of savory snacks along with a leading United States frozen foods company. Every single day, our well-loved brands nourish families to allow them to flourish and thrive. These brands include Kellogg’s®, Keebler®, Special K®, Pringles®, Kellogg’s Frosted Flakes®, Pop-Tarts®, Kellogg’s Corn Flakes®, Grain Krispies®, Kashi®, Cheez-It®, Eggo®, Coco Pops®, Small-Wheats®, and much more. To understand more about our responsible business leadership, foods that delight and just how we attempt compare unique car features within our communities all over the world, visit world wide web.kelloggcompany.com.

K-FIN

View original content:http://world wide web.prnewswire.com/news-releases/kellogg-company-sets-date-for-2017-4th-quarter-results-conference-call–webcast-300568457.html

SOURCE Kellogg Company

Related Links

http://world wide web.investor.kelloggs.com

Allscripts Chief executive officer Paul Black on interoperability, provider burnout and much more

data, conceptual, information

Since 2012, Paul Black has offered as Chief executive officer of Chicago-based Electronic health record company Allscripts. He formerly stayed working at Cerner, where he held the COO position, and IBM, where he required on various leadership roles.

Inside a recent phone interview, Black discussed numerous very hot topics in healthcare — including interoperability, artificial intelligence and provider burnout — and just what Allscripts can be.

This exchange continues to be gently edited.

Advertisement

You lately penned your blog publish about why the Veterans administration should concentrate on interoperability. Would you discuss the publish, in addition to what Allscripts does around the interoperability front?

When we move back and check out where healthcare is incorporated in the U.S. circa 2018, you’ll spot the infrastructure today is nearly completely wired. That begets the issue: How do I recieve data in one Electronic health record to a different one?

I take into account that to become a high-class problem. There are answers which are available today, and Allscripts continues to be purchasing one since 2009.

Around the Veterans administration, we’ve had lots of conversations with individuals folks. We’re relatively up to date on which the needs take presctiption that. Exactly what the Veterans administration is about isn’t just the substitute of emr, but additionally connecting with other source systems that sit outdoors the ecosystem. Getting the totality from the veteran’s record is essential.

So how exactly does the drive toward healthcare consumerism affect a technology company like Allscripts?

We’ve used the customer moniker for any lengthy time period. If our vision will be a wide open, connected community of health, additionally, it includes a component where we’re speaking concerning the consumer.

Our method of consumers begins with our FollowMyHealth platform. It doesn’t require the consumer is mounted on an Allscripts EMR. In the finish during the day, I own the data about myself and will be able to grant accept to who examines my record, the way our consumer platform operates.

AI is really a hot subject in healthcare at this time. How’s Allscripts involved in the device learning space?

Allscripts provides extensive data that people look at and evaluate. There are several 40 million lives we have deidentified within our data constructs today that provide us insight and also the capacity to complete research. We’ve people whose work on we are dedicated to insights that emerge from studying that data.

Should you consider the way your experience when you are shopping works, the 3rd or 4th time you shop on the site, it’ll begin suggesting products. There isn’t any reason exactly the same kind of learning can’t be relevant to what sort of doctor practices. Equally around the financial side, you can see patterns of consumption according to the position of the clinic and also the patient.

What exactly are your ideas on provider burnout? How’s Allscripts trying to promote provider wellness?

Another reality of everybody now utilizing a product is that you have many people who’ve in the past not used at all computers prior to being exposed to numerous clinical, financial and quality metrics.

Because the Significant Use needs came lower, sometimes that [data entry] burden has fallen around the caregiver, and particularly the doctor. There is a term known as “pajama models,” where they’re finishing the work they do after hrs.

All EMRs make some contribution for this effect. Therefore, so what can we all do to assist several experienced humans whose time is efficacious?

The device learning I spoken 1 minute ago — that sort of useful computerization could be advantageous to those people. The 2nd factor is: What is the method for us to possess less keyboard needs? Are you able to move toward a keyboardless visit? There’s value the automation will bring these to help augment the patient’s experience of the concern setting.

What else does Allscripts have coming lower the pipeline?

2017 is a great year for Allscripts. Because of the job that’s been happening the final 5 years, we have seen in the finish of 2017 a obvious separation of Allscripts, Cerner and Epic [from all of those other pack]. There’s lots of focus on our clients’ part to continue to possess belief that we’re the best supplier to utilize with an ongoing basis.

Photo: MATJAZ SLANIC, Getty Images

Megaport Achieves AWS Networking Competency Status

Queensland, Australia, 12 ,. 4, 2017 /PRNewswire/ — Megaport Limited (ASX: MP1) (“Megaport”), a worldwide leading Network like a Service (NaaS) provider, announced today it has achieved Amazon . com Web Services (AWS) Networking Competency status. This designation sees that Megaport provides industry-leading Software Defined Networking (SDN) technology across 179 locations to assist customers adopt, develop, and deploy systems on AWS.

Experienceing this AWS Networking Competency differentiates Megaport being an AWS Partner Network (APN) member that gives specialized shown technical proficiency and proven customer success with specific concentrate on Networking according to scalable, secure, direct connectivity. To get the designation, APN Partners must possess deep AWS expertise and deliver solutions seamlessly on AWS.

“The innovation and breadth of services at AWS will always be very appealing to our enterprise customers,” stated Vincent British, Ceo, Megaport. “Our SDN helps enterprises quickly connect with AWS Direct Connect. The vast achieve of Megaport’s global network footprint increases ease of access to AWS services by enabling AWS Direct Connect in new regions and empowers enterprises having a consumption-based networking model. We are honored to possess achieved AWS Networking Competency status once we still develop features to really make it even simpler to obtain our customers connected.”

AWS is enabling scalable, flexible, and price-effective solutions from startups to global enterprises. To aid the seamless integration and deployment of those solutions, AWS established the AWS Partner Competency Program to assist customers identify Talking to and Technology Partners within the APN with deep industry expertise and experience.

With the Megaport SDN, enterprises can connect with 10 AWS regions and also over 25 AWS Direct Connect locations all over the world in under one minute. Megaport enables a pay-as-you-go model that produces a convenient and price-efficient way to connect with the cloud. With Megaport, enterprises can connect with multiple AWS Regions, around the world, from one interconnection point. Which means that they are able to leverage multi-region at a small fraction of the typical cost.

About Megaport

Megaport may be the global leading provider of Elastic Interconnection services. Using Software Defined Networking (SDN), the business’s global platform enables people to quickly connect their network with other services over the Megaport Network. Services could be directly controlled by customers via cellular devices, their computer, or our open API. The Business’s extensive footprint in Australia, Asia Off-shore, The United States, and Europe, supplies a neutral platform that spans many key data center providers across various markets.

Established in 2013 and founded by Bevan Slattery, Megaport built the earth’s first SDN-based Elastic Interconnection platform made to supply the most dependable, seamless, as well as on-demand method for enterprises, systems, and services to interconnect. Brought by Vincent British, Megaport continues to be built with a highly experienced team with extensive understanding in building massive global carrier systems and connects over 750 customers throughout 179 data centres globally. Megaport is definitely an Alibaba Cloud Technology Partner, Oracle Cloud Partner, APN Technology Partner, Microsoft Azure ExpressRoute Partner, and Google Cloud Interconnect Partner.

Megaport, Virtual Mix Connect, VXC, and MegaIX are registered trademarks of Megaport (Services) Pty Limited ACN 607 432 646.

To understand more about Megaport, check out: world wide web.megaport.com.

MEDIA Queries

Megaport Contact:
Camille Denning
+61-473-088-7400
[email protected]

View original quite happy with multimedia:http://world wide web.prnewswire.com/news-releases/megaport-achieves-aws-networking-competency-status-300565699.html

SOURCE Megaport Limited

Related Links

http://world wide web.megaport.com

Practice management IT startup provides a method to preserve data from patients’ after-hrs calls

Among the overlooked pitfalls facing physicians is after-hrs calls. The data can take a backseat, queries can explore the shuffle or aren’t addressed inside a timely way, or even the on-call physician doesn’t have the patient’s chart during the time of the phone call. Another risk is the fact that potentially crucial information from that decision doesn’t get documented which could have serious implications in case of a malpractice suit.

MedXCom was created by a few physicians who lost a malpractice suit partly simply because they lacked the information from your after-hrs call. CEO Henry Kane spoken concerning the company’s method of record and instantly integrate these calls within an interview from MedXCom’s Hoboken, Nj offices.

Ironically, Kane originates from the medical negligence industry where he labored with large physician practices. He noted that most from the after-hour communication from patients is thru a live operator service. He observed these services are usually national or regional and frequently use antiquated technology.

Advertisement

With MedXCom’s approach, patients decide whether or not to leave a voicemail message for that office staff to become clarified the following working day, leave a non-urgent voicemail message for that provider, or interact with the doctor in those days.

When patients want to talk with the company after hrs, they’re recognized by their number, the application instantly delivers relevant personal health information using their Electronic health record, for example allergic reactions, the medication they’re on and last visit notes, Kane noted. The on-call physician can push a control button in order to save the conversation, as well as their publish-call notes, in to the Electronic health record.

Urgent calls are attached to the on-call provider instantly as the phone application displays the patient’s chart.  After the phone call, a hyperlink towards the phone call recording and then any publish call notes instantly flow into the patients EMR record being an encounter.

The prospective markets are practices that take lots of after-hour calls, particularly pediatrics, cardiology, Primary health care provider-GYN, and surgical practices.  The clients are also endorsed through the American Academy of Dental and Maxiofacial Surgeons.

Two kinds of partnerships are helping drive sales. Athenahealth and AdvancedMD are the initial major electronic health record vendors to work with MedXCom and Kane stated his clients are speaking to other people. Medical negligence insurers will also be important partners.

“Medical malpractice carriers told us ‘if you integrate with EHRs we’ll support it.’” NORCAL Group is a such group. It incentivizes physician practices to consider MedX by providing a ten percent discount to individuals which use it.

Although a lot of medical negligence insurance providers offer discounts as high as five percent to take a training course or utilizing a specific medical protocol, Kane claimed that MedXCom may be the first automated tool to garner this type of discount.

“I spent twenty years employed in medical negligence. We designed MedXCom after extensive conversations using the nation’s leading insurer. We requested them what features did they think would substantially reduce risk in after-hrs patient care.  They told us when we could record every after hour call after which fully integrate it in to the Electronic health record, it might be a no-brainer.”

The company has additionally added the opportunity to display data from the patient’s chart instantly, produced a method to enable HIPPA-compliant texting and integrates with 90 % from the live operator services in the united states. The explanation behind this move is to provide a choice for those who still want the private touch of the local operator having a value-added plan to sell full integration using the EHRs, Kane stated.

Up to now, the organization has 3,000 clinical users across 48 states, based on Kane. To date, the organization has guaranteed investment from angels and hasn’t yet required to approach institutional investors for funding, however that could change the coming year as the organization concentrates on scaling the company.

Photo: LDProd, Getty Images 

MedCity ENGAGE, October 23-24 in North Park, concentrates on the most recent strategies and innovations to boost patient engagement, care delivery and company wellness. Use code MCNTAG in order to save $50.

Statement from Broadcasting Board of Governors (BBG) Chief executive officer John F. Lansing Concerning the Russian Federation’s Media Law

WASHINGTON, November. 25, 2017 /PRNewswire-USNewswire/ — President Putin has signed legislation to which foreign media organizations could be considered “foreign agents.”  Russian officials have established that, under this law, much more limitations might be put on the BBG’s systems, including Radio Free Europe/Radio Liberty (RFE/RL) and Voice of the usa (VOA), as well as their services, such as the Moment television and digital network.

RFE/RL, VOA, and yet another systems of U.S. worldwide media will stay dedicated to our mission, stipulated by U.S. law, to supply accurate, objective, and comprehensive journalism along with other happy to our global audiences, including within the Spain.

We’ll study carefully all communications we might receive from Russian government bodies concerning our operations.  While we won’t speculate regarding the effect that any new steps through the Russian government may have on the newspaper work, any portrayal of these steps as reciprocity for U.S. actions seriously distorts reality.  Russian media, including RT and Sputnik, can be employed in the U . s . States and could be, and therefore are, transported by U.S. cable tv outlets and Radio stations.  However, U.S worldwide media, including VOA and RFE/RL, are banned from television and radio in Russia.

Additionally, our journalists on assignment are harassed by Russian government bodies and face extensive limitations on their own work.  RFE/RL contributor Mykola Semena lately was sentenced with a Russian court to have an article he authored, and contributor Stanislav Asayev has been held by Russia-backed separatists in Ukraine.  RFE/RL journalists were knocked lower and kicked during assignment in Russia’s southern area of Krasnodar in March, and VOA correspondent Daniel Schearf continues to be denied a visa to re-enter Russia. 

The BBG could be pleased when the current concentrate on reciprocity between Russian and American media ends by providing U.S. outlets – including U.S. worldwide media for example VOA and RFE/RL – exactly the same legal rights and possibilities in Russia that Russian systems have in the U . s . States.

CONTACT: Nasserie Carew, 202-203-4400, [email protected]

View original quite happy with multimedia:http://world wide web.prnewswire.com/news-releases/statement-from-broadcasting-board-of-governors-bbg-chief executive officer-john-f-lansing-regarding-the-russian-federations-media-law-300561594.html

SOURCE Broadcasting Board of Governors

Related Links

http://bbg.gov

DelMar Presents Positive Interim Is a result of VAL-083 Study in MGMT-unmethylated Recurrent GBM in the Society for NeuroOncology Annual Meeting

VANCOUVER, Bc and MENLO PARK, Calif., November. 21, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Corporation. (NASDAQ: DMPI) (“DelMar” or even the “Company”), a biopharmaceutical company centered on the introduction of new cancer therapies, today provided an introduction to three scientific posters presented in the 22nd Annual Meeting and Education Day’s the Society for Neuro-Oncology (SNO) held on November 16-19, 2017 in Bay Area, CA.

DelMar reported that 96% of patients enrolled were alive during the time of case study and 40% of patients enrolled were reported to possess achieved stable disease as assessed by MRI following treatment with VAL-083 like a single agent.  “Even though it is too soon to interpret overall survival is a result of this research, the substantial disease control observed up to now within the treatment recurrent GBM, ‎an aggressive tumor that may double in dimensions within 6-8 days, is a vital and positive observation at this time,Inch stated Mr. Saiid Zarrabian, DelMar’s Interim Ceo.  

“The promising early observations from your ongoing Phase 2 medical trial of VAL-083 like a potential new treatment choice for MGMT-unmethylated GBM will also be based on extensive preclinical research into VAL-083’s unique mechanism of action,” added Mr. Zarrabian.  “According to these recent data, we feel VAL-083 represents a possible solution for probably the most important unmet medical needs in treating GBM along with other nervous system tumors.”

DelMar provided an update around the company’s ongoing Phase 2 studies inside a poster titled “Numerous Studies with dianhydrogalactitol (VAL-083) in MGMT-unmethylated Glioblastoma,” which is happening together with The College of Texas MD Anderson Cancer Center. This trial is made to enroll as much as 48 patients to find out if VAL-083 treatment improves overall survival when compared with historic reference control. 

  • DelMar reported that 27 subjects happen to be screened and 15 happen to be enrolled because the opening of recruitment in Feb 2017. Up to now, the trial has enrolled for a price in front of initial projections.
  • All patients signed up for the research have recurrent MGMT-unmethylated GBM with radiographic proof of progression and weren’t surgically resected during the time of enrollment.
  • DelMar reported that 96% of patients enrolled were alive during the time of case study and 40% of patients enrolled were reported to possess achieved stable disease following treatment with VAL-083 like a single agent, as assessed by MRI.
  • Enrollment is ongoing and median survival hasn’t yet been arrived at within the trial.
  • Generally, VAL-083 treatment was well tolerated by patients with observed negative effects (myelosuppression) much like prior clinical experience.

The Organization also provided an introduction to the look another Phase 2 medical trial of VAL-083 for recently diagnosed MGMT-unmethylated GBM patients about this poster. In this trial, that was lately initiated at Sun Yat-Sen College Cancer Center, patients is going to be given VAL-083 plus radiotherapy instead of standard-of-care temozolomide plus radiation right in front-line setting. The trial is made to enroll as much as 30 volunteers with MGMT-unmethylated GBM to find out if VAL-083 treatment improves progression free survival (PFS) over a historic reference control. This trial has been supported though DelMar’s collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co., Limited. 

Additionally, DelMar also presented two additional pre-clinical posters throughout the conference: 

  • The Distinct Cytotoxic Mechanism of Dianhydrogalactitol (VAL-083) Overcomes Chemoresistance and offers New Possibilities for Combination Therapy in treating Glioblastoma.

VAL-083 induces potent anti-cancer activity against treatment-resistant cells from glioblastoma, lung, prostate and ovarian tumors via a distinct mechanism of action.  Cancer cells given VAL-083 exhibit persistent DNA double-strand breaks and activation from the homologous DNA repair (HR) system. Activation from the HR product is an indication of VAL-083’s unique anti-tumor activity.

When coupled with topoisomerase or PARP inhibitors, the therapy aftereffect of VAL-083 is elevated inside a synergistic or super-additive manner. Taken together, these data offer the broad potential of VAL-083 like a new treatment against an array of cancers both like a single agent and in conjunction with other established cancer therapies.

  • Dianhydrogalactitol (VAL-083) Overcomes Chemoresistance in Pediatric Malignant Brain Tumors and Displays Synergy with Topoisomerase Inhibitors

Pediatric high-grade glioma (HGG) and medulloblastoma are aggressive childhood brain tumors having a high incidence of recurrence and incredibly couple of patients achieve lengthy-term survival.  VAL-083 demostrates potent activity like a single agent against both chemotherapy-resistant pediatric HGG and medulloblastoma separate from p53 status. DelMar also reported that VAL-083 potentiates radiotherapy and exhibits synergy when in combination with topoisomerase inhibitors, two regimens generally utilized in treating childhood brain tumors. 

“We continue being highly passionate about the potential for VAL-083 like a novel strategy to cancer patients who’ve limited or no treatments,Inch added Mr. Zarrabian. “The superb work done by the world class academic research collaborators and our in-house team presented in the SNO meeting showcases VAL-083’s potential both like a single agent so that as a part of combination therapeutic regimens.” 

DelMar’s poster presentations can be seen within their whole on DelMar’s website at http://world wide web.delmarpharma.com/scientific-publications.html

About VAL-083

VAL-083 (dianhydrogalactitol) is really a “first-in-class”, DNA-targeting agent that introduces interstrand DNA mix-links in the N7-position of guanine resulting in DNA double-strand breaks and cancer cell dying. VAL-083 has shown clinical activity against a variety of cancers including GBM and ovarian cancer in historic numerous studies backed through the U.S. National Cancer Institute (NCI).  DelMar has shown that VAL-083’s anti-tumor activity is unaffected by common mechanisms of chemoresistance in vitro. Further details regarding these studies are available at http://world wide web.delmarpharma.com/scientific-publications.html.

VAL-083 continues to be granted an orphan drug designation through the U.S. Food and drug administration Office of Orphan Products to treat glioma, medulloblastoma and ovarian cancer, as well as in Europe to treat malignant gliomas.

About DelMar Pharmaceuticals, Corporation.

DelMar Pharmaceuticals is centered on the event and commercialization of recent therapies for cancer patients who’ve limited or no treatments.  By concentrating on understanding tumor biology and mechanisms of treatment resistance, the organization identifies biomarkers to personalize new therapies in indications where people are failing, and have become resistant against modern targeted or biologic treatments.

The Business’s current pipeline relies around VAL-083, a “first-in-class,” small-molecule chemotherapeutic having a novel mechanism of action which has shown clinical activity against a variety of cancers including nervous system, ovarian along with other solid tumors (e.g. NSCLC, bladder cancer, mind & neck) in numerous studies backed through the NCI. Based on DelMar’s internal research programs which prior NCI-backed studies, the organization is performing numerous studies to aid the event and commercialization of VAL-083 across multiple oncology indications to resolve significant unmet medical needs.

VAL-083 may also be studied in 2 collaborator-supported, biomarker driven, Phase 2 numerous studies for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance represents a substantial unmet medical need in treating GBM.  DelMar also lately announced the allowance of the separate IND for VAL-083 like a potential strategy to platinum-resistant ovarian cancer.

More information on DelMar’s numerous studies are available on clinicaltrials.gov:  https://world wide web.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs

For more information, check out http://delmarpharma.com/ or contact DelMar Pharmaceuticals Investor Relations: [email protected] / (604) 629-5989.

Interact with the organization on Twitter, LinkedIn, Facebook, and Google+.

Safe Harbor Statement

Any statements found in this pr release that don’t describe historic details may constitute forward-searching statements as that term is determined within the Private Securities Litigation Reform Act of 1995. Any forward-searching statements contained herein derive from current expectations, but they are susceptible to numerous risks and uncertainties. The standards that may cause actual future leads to differ materially from current expectations include, but aren’t restricted to, risks and uncertainties concerning the Company’s capability to develop, market then sell products according to its technology the expected benefits and effectiveness from the Company’s products and technology the supply of considerable additional funding for the organization to carry on its operations and also to conduct development and research, studies and future product commercialization and, the business’s business, research, product, regulatory approval, marketing and distribution plans and techniques. These along with other factors are identified and described in greater detail within our filings using the SEC, including, our current reports on Form 8-K.

View original quite happy with multimedia:http://world wide web.prnewswire.com/news-releases/delmar-presents-positive-interim-results-from-val-083-study-in-mgmt-unmethylated-recurrent-gbm-at-the-society-for-neurooncology-annual-meeting-300560484.html

SOURCE DelMar Pharmaceuticals, Corporation.

Related Links

http://world wide web.delmarpharma.com

DiA Imaging Analysis enters partnership with GE Healthcare on automatic imaging analysis tools

“We’re very happy to work with DiA Imaging Analysis. GE Healthcare includes a lengthy good reputation for getting innovative methods to our customers all over the world,Inch Take advantage of Walton, gm of GE Healthcare Primary & Affordable Care commented. “These power tools will bring new abilities to ultrasound at the purpose of care.” 

Hila Goldman Aslan, DiA’s Ceo and Co-Founder, mentioned, “We’re excited with this particular collaboration, and expect to using a market leader for example GE Healthcare.  Our advanced automated tools for reason for care echo ultrasound analysis are first to promote, and we’re intending to soon launch additional automated imaging analysis tools included in our vision to enhance patient care.”

Arnon Toussia-Cohen, DiA’s Chairman and V . P . of economic Development, added.  “Up to now, we’re the only real company that provides automated tools for handheld ultrasound devices and we’re proud to work with GE Healthcare to supply immediate information at the purpose of care.”

The Organization is going to be showing its systems in the approaching Radiological Society of The United States (RSNA) meeting in Chicago in the Machine Learning Showcase,booth #8545.

DiA Imaging Analysis is really a medical imaging analysis software company supplying fully automated, implementable tools which allow quick, objective, and accurate imaging analysis, by having an initial concentrate on echocardiography.

Hollister begins construction on new manufacturing facility in Lithuania

Printed 08 November 2017

Hollister Incorporated, a worldwide medical device manufacturer, held a groundbreaking ceremony signifying the beginning of construction on the manufacturing facility within the Kaunas FEZ (Free Economic Zone) region of Lithuania.

The multi-stage project represents a business investment well over $58 million (€50 million) and it is likely to create greater than 300 jobs within the next many years. Upon opening in mid-2019, the brand new plant will produce ostomy-maintenance systems with intends to expand production to incorporate continence-maintenance systems.  

The groundbreaking ceremony and reception were attended by: Hollister Incorporated President and Chief executive officer George Maliekel Senior VP of Research & Development and Global Operations James Humphries VP Human Sources Suzanne Erickson VP and CFO Take advantage of Keeley VP of worldwide Operations Brendan Sugrue and Senior Director Global Manufacturing William Ciehanski.  

“Our decision to purchase this major expansion project in Lithuania is made after very thoughtful consideration,” stated Hollister Incorporated President and Ceo George Maliekel. “This is really a key proper initiative for that ongoing development of our organization as well as for our customers all over the world who rely on medical products from the greatest quality. I wish to personally thank our partners within Lithuania who’ve helped us to organize and get ready for this special day.” 

Representing the Kaunas FEZ in the groundbreaking ceremony were Kaunas City Mayor Visvaldas Matijosaitis, and Director General of Invest Lithuania Mantas Katinas, along with other partners. Based on Mr. Katinas, “Hollister Incorporated selected the united states, region and city not just for that ideal geographical factors and investment atmosphere, but in addition for the strong skills and values in our local workforce.“  

“Very at the start of the website buying process, we recognized the Kaunas region of Lithuania offered a perfect European location, an inviting business atmosphere, strong community support, as well as an ideal mixture of infrastructure and talent to satisfy our manufacturing needs,” Mr. Maliekel mentioned. 
“Our new manufacturing facility within Kaunas won’t allow us to to satisfy the growing requirements of our customers – particularly our customers in Europe – but probably allow us to to satisfy the worldwide healthcare challenges from the twenty-first century.” 

The abilities and talent from the local population were critical components in deciding to construct the brand new facility in Lithuania. The cultural ‘fit’ between your company’s culture and also the people through the region were also very important. Educational possibilities were a substantial factor too. That’s the reason Hollister Incorporated is dedicated to working carefully with local educational facilities, such as the Kaunas College of Technology and also the Lithuanian College of Health Sciences, in addition to institutions across the nation to assist enhance programs in research, engineering and technology to build up exceptional graduates and additional strengthen the neighborhood talent market.

The organization has hired a couple of engineers from Lithuania who’ll begin their work at its Ballina, Ireland plant. They’ll go back to the Kaunas plant following the first phase of construction is finished in 2019. 

Source: Company Pr Release

First JCS Worldwide Youthful Creatives Award Presented At 2017 Worldwide Emmy World Television Festival

NEW You are able to, November. 18, 2017 /PRNewswire/ — JCS Worldwide President Michal Grayevsky presented today, the very first ever JCS Worldwide Youthful Creatives Award in the 2017 Worldwide Emmy World Television Festival. The 3 winners—Eisa Alhabib of Kuwait, Ewing Luo of China and Roberto Pino Almeyda of Chile—each produced exceptional 1-minute short videos on the party’s theme of ladies Peacemakers. The ceremony occured throughout the traditional annual Nominee Medal Ceremony for that 2017 Worldwide Emmy Awards Nominees in the Worldwide Emmy World Television Festival, held in the Sofitel Hotel in New You are able to.

“Today, we celebrate three youthful creatives whose work promotes peace over the globe—and the ladies who allow it to be all possible,” stated Michal Grayevsky, President of JCS Worldwide along with a Board Person in the Worldwide Academy. “We’re so grateful towards the Worldwide Academy for his or her remarkable work. This primary year was superb, so we expect to partnering for years to come.Inch

The JCS Worldwide Youthful Creatives Award was handed to 3 gifted youthful artists who posted 1-minute videos concentrating on Women Peacemakers. Eisa Alhabib of Kuwait directed “Domestic Cycle,” which movingly portrays one youthful woman’s efforts to produce peace in their family. Ewing Luo of China directed “The Peacemaker from Nanking,” an uplifting depiction of the youthful lady from Nanking, China, who decides to invest her summer time like a peacemaker in Iraq. Roberto Pino Almeyda of Chile directed “Nosotras,” which concentrates on an seniors lady reflecting on the duration of progress.

“I am honored to get the JCS Worldwide Youthful Creatives Award,” stated award champion Eisa Alhabib of Kuwait. “Like a youthful artist, I am so grateful that organizations like JCS Worldwide and also the Worldwide Academy have recognized my work.”

“My short video, ‘The Peacemaker from Nanking,’ is really a deeply personal project,” stated award champion Ewing Luo of China. “Receiving this award is a vital part of my creative development, and that i hope it inspires other potential peacemakers and artists.”

“It has been this kind of exciting process for me personally being an artist,” stated award champion Roberto Pino Almeyda of Chile. “To become honored like a Youthful Creative inspires me to pursue my artistic ambitions within the a long time.Inch

The JCS Worldwide Youthful Creatives Award was available to contestants from around the globe between 18 and 29, who have been asked to submit a 1-minute video on the party’s theme of ladies Peacemakers. Three winners were selected in line with the criteria of concept, execution, character development and creativeness. The panel of jurors was made up of:

  • Jenna Arnold, Co-Founding father of ORGANIZE
  • Camille Bidermann, Executive Director from the Worldwide Academy of Television Arts and Sciences
  • Sean Cohan, President of Worldwide & Digital Media in a&E Systems
  • Susan Ennis, EVP of Cinemax
  • Michal Grayevsky, President of JCS Worldwide
  • Barbara Kopple, Film Producer and Director
  • Dennis Paul, Founder and Managing Person in Thyra Global Management
  • Muna Rihani, Chairman of U.N. Women for Peace Association (UNWFPA)
  • Isiah Thomas, President of NY Liberty

About JCS Worldwide
JCS Worldwide is really a global media company headquartered in New You are able to City. Founded in 1979, JCSI pioneered the main one-stop shop concept, offering full-service production abilities, from conception to execution, all in one place. For many years, JCSI has introduced together media outlets from around the globe and helped them fulfill their mission. Now, JCSI is developing a unique new media platform for youthful companies, entrepreneurs and inventive talent, helping its partners realize their potential and scale. The organization is independently held through the Ronald S. Lauder Group

Concerning the Worldwide Academy of Television Arts & Sciences
The Worldwide Academy of Television Arts & Sciences is really a membership based organization made up of leading media and entertainment figures from over 60 countries and 500 companies all sectors of television including internet, mobile and technology. The Academy’s yearly schedule of occasions includes the esteemed Worldwide Emmy® Awards locked in New You are able to, The Worldwide Emmy® Kids Awards at MIPTV and a number of industry occasions for example Academy Day, The Worldwide Emmy® World Television Festival and Panels on substantive industry topics. The Worldwide Academy of Television Arts & Sciences recognizes excellence in television created outdoors of the U . s . States, in addition to US Primetime programs created in languages apart from British, using the esteemed Emmy® Award. Presently celebrating programming across varied areas including: Arts Programming, Current Matters, Comedy, Documentary, Drama Series, News, Non-Scripted Entertainment, Short-Form Series, Telenovela, and television Movie/Small-Series, additionally, it recognizes excellence in Performances, Kids programming and Digital. To learn more, visit world wide web.iemmys.tv  

Contact: Avi Small, [email protected], 646-676-4485

View original quite happy with multimedia:http://world wide web.prnewswire.com/news-releases/first-ever-jcs-worldwide-youthful-creatives-award-presented-at-2017-worldwide-emmy-world-television-festival-300559109.html

SOURCE JCS Worldwide

Xeltis raises &euro45m financing to succeed aortic and lung valve programs

Printed 16 November 2017

Clinical-stage medical device company Xeltis has completed an oversubscribed €45m in series C financing to succeed its programs on aortic and lung valves.

The funding round was brought with a global proper investor with participation from investment capital fund Ysios Capital and numerous large eco-friendly. Existing institutional investors (LSP, Kurma Partners and Mire Partners) and investors also took part in the financial lending.

The Series C financing will support continuation of clinical activities and acceleration of product and market development for that company’s novel aortic and lung valve programs. This is actually the largest investment round for any private medical device company in Europe in 2017.

“Xeltis is raring to supply patients who require heart valve substitute with a brand new option offered through our restorative technology, to ultimately enhance their lives and lower healthcare system costs,” stated Xeltis Ceo (Chief executive officer) Laurent Grandidier. “This robust financing gives us the sources essential to catapult our strategy forward – supporting quick growth of our aortic and lung valve programs and strengthening our mission to redefine heart valve substitute therapy.”

Xeltis’ heart valves let the patient’s own body to naturally restore a brand new heart valve via a therapeutic approach known as Endogenous Tissue Restoration (ETR). With ETR, a person’s healing system develops tissue that pervades Xeltis’ heart valve, developing a brand new, natural and completely functional valve there. As ETR occurs, Xeltis implants are progressively absorbed through the body. ETR is enabled by bioabsorbable polymers according to Nobel Prize awarded science.

Ongoing Trial Programs 

At TCT 2017, Xeltis announced the most recent study is a result of the Xeltis preclinical aortic valve program throughout a session focused on its innovative technology. The 12-month preliminary aortic valve data demonstrated promising results with higher hemodynamic performance and completely functional valves in vivo 12 several weeks after implantation.

The very first practicality medical trial for Xeltis’ lung valve, Xplore-I, is going ahead in Asia and europe. In The month of january, the U.S. Fda (Food and drug administration) approved an Investigational Device Exemption (IDE) for Early Practicality Study (EFS) to implant Xeltis’ lung valve in 10 patients. Four prominent U.S. centers are actually taking part in the medical trial known as Xplore-II.

Formerly, Xeltis shared as much as 31-month data from the pediatric practicality study of the vascular graft. The research demonstrated positive functionality results without any device-related adverse occasions, and significant improvement in patients’ general conditions.

Xeltis is presently investigating additional applying its innovative method of restore other heart valves and bloodstream vessels.

Source: Company Pr Release